ILSI-Biomed Israel

Meet The Speakers: Shlomo Yanai

The ILSI-BioMed week is closer every day. It will be opened by a keynote address by Mr. Shlomo Yanai, President and CEO of Teva, Israel. Shlomo Yanai has been the President and Chief Executive Officer of Teva since March 2007. Prior to joining Teva, Mr. Yanai was President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006. Previously, Mr. Yanai served in the Israel Defense Forces (the "IDF") for 32 years, where he achieved the rank of Major General, t...

Job Offer in Israel

Teva Pharmaceuticals Ltd. is looking for Clinical Supply Chain Planner Design, plan, execute and manage supply chain for worldwide clinical studies in accordance with international guidelines and regulations. Setup reliable global clinical supply chain for new studies in various stages. Manage outsourced IT, distribution and packaging vendors and resolve effectively any encountered operational issues Requirements: Industrial Engineer Experience in supply chain a plus Very good communica...

Job Offers in Israel

Reseach Assistant - recombinant protein purification Looking for a Research Assistant for a small biotech company, preferably with previous experience, to work in the downstream department, including characterization and purification of recombinant proteins. Must be able to read and write in English. B.Sc. or M.Sc. in biochemistry or biotechnology. Please send cv's (as Word documents) to Rachel.Schecter@Managingprosolutions.com Teva Pharmaceutical Industries is looking for an Inhalers QA...

Molecular imaging to diagnose, monitor and treat disease

Molecular probes from Israel's Aposense show areas of disease on a cellular level and can even provide a picture that reveals the efficacy of chemotherapy. Israeli biotech company Aposense offers a futuristic way of diagnosing, monitoring and treating disease through molecules designed to detect cell death (apoptosis). While apoptosis is a universal process in cell biology, it plays a role in most medical disorders. Targeting cells undergoing apoptosis, for imaging or delivering therapy, can ...

Teva’s layoff at its Irvine facility

Teva Pharmaceuticals Inc. , an Irvine drug maker, will cut 200 jobs this year, including 195 as of Feb. 6, the company confirmed. “Our Irvine, California facility has been under a voluntary manufacturing and distribution hold since April 2010,” said Denise Bradley, Teva spokeswoman in a company statement. “Prior to this reduction, we have not laid off any employees as a result of this voluntary production hold. The jobs which are being eliminated are all various production jobs and support st...

For Teva Pharmaceutical industries, Clinical Supply Chain – QA Specialist

CSU QA-oversees the implement of standard operation procedures relating to activities in the clinical supply unit and compliance with the requirements (of Good Manufacturing Practice (GMP QA & QC of activities of the clinical supply chain relating to packaging of the clinical supplies for clinical studies and ensure compliance with cGMP guidelines, Teva standard operating procedure (SOP) and national and international laws applicable in the relevant countries. Activities include: Approva...

New Research From Israel: Aposesne

In a special Jewish Week feature, three Israeli cutting edge research projects are being introduced. One of them is Aposesne, an Israeli pharmaceutical company that is targeting a process that is integral to nearly every illness — apoptosis, or cellular death. Photo credit: ardelfin from morguefile.com “Apoptosis is associated with almost every medical disorder,” said Yoram Ashery, CEO of Aposense, a clinical stage molecular imaging and drug development company that completed its Initial P...

MediWound applies for EMA on a wound treatment drug

Clal Biotechnology Industries announced that MediWound has applied to the European Medicines Agency (EMA) for marketing approval of its new drug, Nexobrid, previously known as Debrase. After the completing of Phase III, the drug now is submitted through the centralized procedure of approval. Succesful completing of this process, which is expected to take about a year, will allow marketing the drug in all EU member states. Exclusive distribution rights belong to Teva Pharmaceutical Industr...

Early Initiation of Treatment with Copaxone Provides Greater Effects in Delaying Conversion to Clinically Definite MS

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone® (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study. Early treatment with Copaxone reduce...